Oral Liken Planusta Kandidiazis: Aşırı Topikal Kortikosteroid Kullanımına Bağlı Komplikasyon

Topical steroids represent the mainstay of management for symptomatic oral lichen planus (OLP), owing to their effectiveness in alleviating pain and inflammation. However, their use may result in adverse effects, such as secondary oral candidiasis (OC), influenced by factors including their potency, duration and frequency of use, and site of application. This study presents a case of OC following topical steroid therapy for OLP, emphasizing the importance of patient compliance in treatment. A 78-year-old woman diagnosed with cutaneous lichen planus four months prior was referred to our clinic for evaluation of new oral lesions. Erosive OLP lesions on the buccal and labial mucosa and tongue were noted upon intraoral examination. The patient was prescribed mometasone furoate 0.05% spray to be used twice daily. As a result of the patient using the medication at a higher dose and frequency than recommended, pseudomembranous OC was noted on the buccal and soft palate mucosae at the follow-up appointment two weeks later. The patient was prescribed an oral suspension of nystatin (100,000 IU) for gargling four times a day, and complete resolution of the OC was achieved within a period of 14 days. Subsequently, the OLP lesions reverted to a reticular form with appropriate use of the topical steroid. The patient remains under regular follow-up at our clinic. Secondary OC may obscure and/or aggravate the clinical features and symptoms of OLP, potentially hindering effective management. Close monitoring of pharmacological therapy and early intervention for secondary OC are vital in achieving optimal treatment outcomes.